HNGE shareholder plans sale of 15,000 common shares under Rule 144

HNGE has a shareholder filing a notice of proposed sale under Rule 144 for up to 15,000 shares of common stock.

Rhea-AI Filing Summary

HNGE has a shareholder filing a notice of proposed sale under Rule 144 for up to 15,000 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $708,750.00, based on the information provided. The filing notes that 37,919,155 shares of this class were outstanding, and the approximate sale date listed is 12/22/2025 on the NYSE.

The 15,000 shares to be sold were acquired on 04/01/2023 as performance stock units from the issuer. Over the prior three months, the same account completed a Rule 10b5-1 sale of 15,000 common shares on 11/21/2025 for gross proceeds of $683,487.00. By signing the notice, the seller represents that they do not know of undisclosed material adverse information about the issuer’s operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the HNGE Form 144 filing disclose?

The notice discloses that a shareholder of HNGE intends to sell up to 15,000 shares of common stock under Rule 144, using Morgan Stanley Smith Barney LLC as broker, with an approximate sale date of 12/22/2025 on the NYSE.

How many HNGE shares are planned to be sold and what is their market value?

The filing lists 15,000 common shares of HNGE to be sold, with an aggregate market value of $708,750.00 based on the figures provided.

How were the HNGE shares being sold under Rule 144 acquired?

The 15,000 HNGE common shares were acquired on 04/01/2023 as performance stock units from the issuer, with the acquisition and payment date both shown as 04/01/2023.

How many HNGE shares of this class are outstanding?

The notice states that there are 37,919,155 shares of the relevant class of HNGE common stock outstanding at the time referenced.

What recent HNGE share sales has this seller made in the last three months?

The filing reports 10b5-1 sales for James Pursley of 15,000 HNGE common shares on 11/21/2025, generating $683,487.00 in gross proceeds.

What representation does the HNGE shareholder make in this Rule 144 notice?

By signing, the seller represents that they do not know any material adverse information about HNGE’s current or prospective operations that has not been publicly disclosed, and if relying on a Rule 10b5-1 plan, that this representation applies as of the plan’s adoption or instruction date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/22/2025 - 04:24 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001783108
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Hinge Health, Inc.
SEC File Number	001-42657
Address of Issuer	455 Market Street, Suite 700 San Francisco CALIFORNIA 94105
Phone	4157262206
Name of Person for Whose Account the Securities are To Be Sold	JAMES PURSLEY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	15000	708750.00	37919155	12/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/01/2023	Performance Stock Units	Issuer			15000	04/01/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JAMES PURSLEY 455 Market Street, Suite 700 San Francisco CA 94105	Common	11/21/2025	15000	683487.00

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of performance stock units during the period of 04/01/2023 through 03/31/2025.
Date of Notice	12/22/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ James Pursley
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)